Direct cardiac effects of As2O3 in rabbits: Evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration

Toxicology and Applied Pharmacology

Volumn 189, Issue 3, 2003, Pages 214-220

  Wu, Mei Hwan ^a   Lin, Chun Jung ^b   Chen, Chi Long ^c   Su, Ming Jai ^b   Sun, Selma Siu Man ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Chinese Medical School   (Taiwan)

Author keywords

Arsenic trioxide; Electrophysiology; Heart

Indexed keywords

ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE;

ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CARDIOTOXICITY; CHRONIC TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HEART CONDUCTION; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; NONHUMAN; QT INTERVAL; RABBIT;

ORYCTOLAGUS CUNICULUS;

EID: 0037941263     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-008X(03)00127-3     Document Type: Article

References (22)

1. Bazett H.C. An analysis of time relations of electrocardiogram. Heart. 7:1920;353-370.
2. Carmignani M., Boscolo P., Castellino N. Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch. Toxicol. 8:(Suppl.):1985;452-455.
3. Chiang C.E., Luk H.N., Wang T.M., Ding P.Y.A. Prolongation of cardiac repolarization by arsenic trioxide. Blood. 15:2002;2249-2252.
4. Eller, P.M., Cassinelli, M.E., 1994. NIOSH Manual of Analytical Methods, 4th ed. U.S. Department of Health and Human Services, Center for Disease Control and Prevention, National Institute for Occupational Safety and Health.
5. Giles W.R., Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J. Physiol. 405:1988;123-145.
6. Goldsmith S., From A.H. Arsenic-induced atypical ventricular tachycardia. N. Engl. J. Med. 303:1980;1096-1098.
7. Huang C.H., Chen W.J., Wu C.C., Chen Y.C., Lee Y.T. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. PACE. 22:1999;965-967.
8. Huang S.Y., Chang C.S., Tang J.L., Tien H.F., Kuo T.L., Huang S.F., Yao Y.T., Chou W.C., Chung C.Y., Wang C.H., Shen M.C., Chen Y.C. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br. J. Haematol. 103:1998;1092-1095.
9. Little R.E., Kay G.N., Cavender J.B., Epstein A.E., Plumb V.J. Torsade de pointes and T-U wave alternans associated with arsenic poisoning. PACE. 13:1990;164-170.
10. Ks blockade at high heart rate in guinea pig and rabbit. Circulation. 104:2001;951-956.
11. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., Wu W., Zhang F.Q., Chen Y., Zhou L., Li J.M., Zeng X.Y., OuYang R.R., Yuan M.M., Ren M.Y., Gu F.Y., Cao Q., Gu B.W., Su X.Y., Chen G.Q., Xiong S.M., Zhang T.D., Waxman S., Wang Z.Y., Chen Z., Hu J., Shen Z.X., Chen S.J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients . Blood. 94:1999;3315-3324.
12. Ohnishi K., Yoshida H., Shigeno K., Nakamura S., Fujisawa S., Naito K., Shinjo K., Fujita Y., Matsui H., Takeshita A., Sugiyama S., Satoh H., Terada H., Ohno R. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intem. Med. 133:2000;881-885.
13. Priori S.G., Barharin J., Hauer R.N., Haverkamp W., Jongsma H.J., Kleber A.G., McKenna W.J., Roden D.M., Rudy Y., Schwartz K., Schwartz P.J., Towbin J.A., Wilde A. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the European Society. Eur. Heart J. 20:1999;174-195.
14. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:1997;3354-3360.
15. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339:1998;900-905.
16. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., Stone R.M., Kalaycio M., Scheinberg D.A., Steinherz P., Sievers E.L., Coutre S., Dahlberg S., Ellison R., Warrell R.P. Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19:2001;3852-3860.
17. Soignet S.L., Maslak P., Wang Z.G. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1998;1341-1348.
18. Stevens, J., 1996. Repeated measures analysis, in: Applied Multivariate Statistics for the Social Sciences, third ed. Erlbaum Hillsdale, New Jersey, pp. 450-478.
19. St. Petery J., Gross C., Victorica B.E. Ventricular fibrillation caused by arsenic poisoning. Am. J. Dis. Child. 120:1970;367-371.
20. Tan H.L., Hou C.J., Lauer M.R., Sung R.J. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann. Intern. Med. 122:1995;175-183.
21. Unnikrishnan D., Dutcher J.P., Lucariello R., Api M., Garl S., Wiernik P.H., Chiaramida S. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 97:2001;1514-1516.
22. Wu M.H., Su M.J., Lee S.S., Young M.L. The electrophysiological effects of antiarrhythmic potential of a secoaporphine, N-allylsecoboldine. Br. J. Pharmacol. 113:1994;221-227.